Significant Trade Imbalance in Pharmaceutical Sector
In a striking revelation of Morocco's trade dynamics, Eurostat has reported that the country imported over €660 million (approximately $716 million) in medical and pharmaceutical products from the European Union last year. In stark contrast, Morocco's exports to the EU were a mere €21.5 million, illustrating a pronounced trade imbalance within the pharmaceutical sector. This disparity underscores the challenges Morocco faces in achieving a balanced trade relationship with the European bloc, particularly in crucial sectors like healthcare.
EU's Booming Pharmaceutical Export Market
The European Union's pharmaceutical market has demonstrated remarkable growth, with EU countries exporting more than €366 billion in medical and pharmaceutical products worldwide in 2025. This surge in exports is juxtaposed with imports that reached €145.7 billion, resulting in an impressive trade surplus of over €220 billion, as detailed by Eurostat. Notably, exports have seen a year-on-year increase of 16%, while imports rose by 21%, a significant jump from €120 billion in 2024. Ireland emerged as the leading EU exporter to non-member countries, shipping €93.8 billion worth of products, followed by Germany and Belgium with nearly €68 billion and over €38 billion, respectively. On the import front, Italy stood out as the largest importer from outside the EU, with €27.5 billion in imports.
The United States continues to be the foremost destination for EU pharmaceutical exports, accounting for more than 43% of total shipments, worth over €160 billion. Other significant markets include Switzerland, with exports exceeding €59 billion, and the United Kingdom, which ranked third with over €20 billion in exports. On the import side, the majority of EU pharmaceutical products came from the United States, Switzerland, and China, indicating a strong reliance on these markets.
According to Eurostat, the EU's pharmaceutical exports have experienced consistent growth since 2015, outpacing imports and driving the trade surplus from €69 billion to a remarkable €221 billion by 2025. During this period, imports have increased by 88%, while exports have surged by 151%, highlighting the sector's robust performance. Despite occasional fluctuations in annual growth rates, the trade landscape has remained predominantly positive over the last decade, with only isolated declines in imports in 2018 and exports in 2023, reflecting the resilience of the pharmaceutical trade.
As reported by en.hespress.com.
